Pear Therapeutics, Inc. announced today that it has entered into agreements with multiple technology companies, including Empatica Inc., etectRx, Inc., and KeyWise, Inc. The new technologies complement the voice-based biomarkers previously licensed from Winterlight Labs. These new agreements bolster Pear’s Prescription Digital Therapeutics (PDT) platform, by adding to its library of digital biomarkers, machine learning algorithms, sensor-based technologies, and digital therapeutics. [Read more…] about From digital therapeutics to personalized mental health solutions: Pear Therapeutics expands platform via partnerships with Empatica, etectRx, KeyWise, and Winterlight
Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). [Read more…] about The new frontier in neurocognitive monitoring and dementia screening: the Apple Watch
Mindstrong scores $100M to monitor wellness via smartphone behaviors (MobiHealth News):
This morning digital mental health platform Mindstrong scored a whopping $100 million in Series C funding.
While Mindstrong has a history of solid funding rounds, this amount will more than double its total funding. In 2017 it got its first $14 million cash infusion. That was followed by a $15 million Series B funding round in June of 2018, which got a $31 million add-on in January of 2019, bringing the company’s total funding to just under $60 million before this news.
The company was first founded in 2014, but it made a splash in 2017 when former NIMH director Dr. Thomas Insel left his position at Verily to take on the role as president at Mindstrong. Insel is still involved in the company today in an advisory role…The technology also has a digital biomarker component. This can track a patient’s smartphone behaviors. While the startup will not see what a patient is doing on their phone, it can monitor how a patient taps, scrolls and types. It can look for indicators of stress, depression or other mental health factors.
Ana Maiques, CEO and founder of neurotech company Neuroelectrics, writes up a compelling case in her recent article, summarized thus:
“I strongly believe that Neurotech entrepreneurs can not afford not to be involved in neuroethics. It is simply not an option anymore.”
I share that belief and would like to take it one step further:
“I strongly believe that healthcare practitioners, researchers, executives and regulators can not afford not to be involved in neuroethics. It is simply not an option anymore.”
“Aural Analytics, a startup using speech analytics algorithms to gauge changes in brain health, has raised $4.3 million in seed funding … The artificial intelligence engine collects speech samples through a smartphone or tablet app, and uploads these to a cloud server for analysis. From these, [Read more…] about Startup Aural Analytics raises $4.3M to monitor neurological health by analyzing speech patterns
Psychiatric diagnosis ‘scientifically meaningless’ (Science Daily):
“A new study, published in Psychiatry Research, has concluded that psychiatric diagnoses are scientifically worthless as tools to identify discrete mental health disorders.
The study, led by researchers from the University of Liverpool, involved a detailed analysis of five key chapters of the latest edition of the widely used Diagnostic and Statistical Manual (DSM), on ‘schizophrenia’, ‘bipolar disorder’, ‘depressive disorders’, ‘anxiety disorders’ and ‘trauma-related disorders’ [Read more…] about Study finds psychiatric diagnoses to be ‘scientifically meaningless’